{"title":"进行性多发性硬化症的生物标志物:最新综述","authors":"S. Esmaeili, A. Zabeti","doi":"10.24018/ejmed.2023.5.4.1760","DOIUrl":null,"url":null,"abstract":"\n\n\nMultiple sclerosis (MS) may begin with a relapsing-remitting course followed by insidious disability worsening independent of clinically apparent relapses. Sometimes the progression is subtle and cannot be detected with routine clinical and imaging assessments. In this review, we focus on emerging biomarkers that can be representatives of MS progression. Early detection of MS progression will result in choosing the appropriate treatments which would result in better long-term outcomes.\n\n\n","PeriodicalId":113708,"journal":{"name":"European Journal of Medical and Health Sciences","volume":"50 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biomarkers in Progressive Multiple Sclerosis: An Updated Review\",\"authors\":\"S. Esmaeili, A. Zabeti\",\"doi\":\"10.24018/ejmed.2023.5.4.1760\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n\\n\\nMultiple sclerosis (MS) may begin with a relapsing-remitting course followed by insidious disability worsening independent of clinically apparent relapses. Sometimes the progression is subtle and cannot be detected with routine clinical and imaging assessments. In this review, we focus on emerging biomarkers that can be representatives of MS progression. Early detection of MS progression will result in choosing the appropriate treatments which would result in better long-term outcomes.\\n\\n\\n\",\"PeriodicalId\":113708,\"journal\":{\"name\":\"European Journal of Medical and Health Sciences\",\"volume\":\"50 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Medical and Health Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.24018/ejmed.2023.5.4.1760\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Medical and Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.24018/ejmed.2023.5.4.1760","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Biomarkers in Progressive Multiple Sclerosis: An Updated Review
Multiple sclerosis (MS) may begin with a relapsing-remitting course followed by insidious disability worsening independent of clinically apparent relapses. Sometimes the progression is subtle and cannot be detected with routine clinical and imaging assessments. In this review, we focus on emerging biomarkers that can be representatives of MS progression. Early detection of MS progression will result in choosing the appropriate treatments which would result in better long-term outcomes.